Skip to content
10-K

Annual Report

AEON Biopharma, Inc. AEON

0001837607-26-000019

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 23, 2026 25.3M sh
Shares Diluted FY 2025 · Dec 31, 2025 9.92M sh
Shares Diluted FY 2025 · Dec 31, 2024 575.95K sh
Capex FY 2025 · Dec 31, 2025 $4K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$17.31M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$20.29M
Cash And Equivalents FY 2025 · Dec 31, 2025 $3.01M
Cash And Equivalents FY 2025 · Dec 31, 2024 $13K
Current Liabilities FY 2025 · Dec 31, 2025 $6.9M
Current Liabilities FY 2025 · Dec 31, 2024 $14.15M
Total Liabilities FY 2025 · Dec 31, 2025 $60.59M
Total Liabilities FY 2025 · Dec 31, 2024 $31.71M
Current Assets FY 2025 · Dec 31, 2025 $3.4M
Current Assets FY 2025 · Dec 31, 2024 $1.59M
Total Assets FY 2025 · Dec 31, 2025 $5.56M
Total Assets FY 2025 · Dec 31, 2024 $3.14M
Eps Diluted FY 2025 · Dec 31, 2025 −$3.95
Eps Diluted FY 2025 · Dec 31, 2024 $72.93
Eps Basic FY 2025 · Dec 31, 2025 −$3.95
Eps Basic FY 2025 · Dec 31, 2024 $77.74
Sga Expense FY 2025 · Dec 31, 2025 $12.21M
Sga Expense FY 2025 · Dec 31, 2024 $13.64M
Rd Expense FY 2025 · Dec 31, 2025 $4.09M
Rd Expense FY 2025 · Dec 31, 2024 $14.18M
Net Income FY 2025 · Dec 31, 2025 −$39.22M
Net Income FY 2025 · Dec 31, 2024 $42.01M
Operating Income FY 2025 · Dec 31, 2025 −$12.8M
Operating Income FY 2025 · Dec 31, 2024 $72.99M